Randomized trial of telmisartan and/or enalapril on renoprotective effects for patients of chronic renal diseases with hypertension.

UMIN ID: C000000299

Registered date:21/12/2005

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Chronic Kidney Diseases
• Date of first enrollment: 2005/12/01
• Target sample size: 150
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Termisartan 20-80 mg daily, over 1 year
Enalapril 2.5 to 10 mg daily, over 1 year
Termisartan 20 to 80 mg and enalapril 2.5 to 10 mg daily, over 1 year

Outcome(s)

• Primary Outcome: Effects of treatments with angiotensin converting enzyme-inhibitor &/or angiotensin receptor blocker on blood pressure, excretion of urinary protein, serum creatinine level and creatinine clearance.
• Secondary Outcome: Adverse effects of angiotensin converting enzyme-inhibitor &/or angiotensin receptor blocker.

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: Patients with allergy for angiotensin converting enzyme-inhibitor or angiotensin receptor blocker, liver injury, or pregnancy. Patients who are inadequate to entry this study by physicians in charge.

Related Information

• Primary Sponsor: Institute of Clinical Medicine, University of Tsukuba
• Secondary Sponsor: Ibaraki Prefectural University of Health Sciences
• Source(s) of Monetary Support: Department account fund